merck kgaa springworks - Search News

News

Merck, Springworks

Reuters on MSN · 17h

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

Bloomberg on MSN · 1d

Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in the country.

Seeking Alpha on MSN · 2d

Merck KGaA to buy Springworks for $3.9 billion

German healthcare and materials group Merck KGaA (OTCPK:MKGAF) to acquire U.S. biotech company SpringWorks Therapeutics (NASDAQ:SWTX) for an equity value of $3.9 billion to boost its cancer drug business,

14h

SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck's Bold $3.9 Billion Bid on SpringWorks: A Game-Changer in Rare Cancer Therapies

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Fierce Pharma1d

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

2d

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results